Her-2/neu in Barrett esophagus: A comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization

Diagnostic Molecular Pathology

Volumn 15, Issue 3, 2006, Pages 125-130

  Rossi, Elisa ^a   Villanacci, Vincenzo ^a   Bassotti, Gabrio ^b   Casa, Domenico Della ^a   Missale, Guido ^a   Minelli, Luigi ^a   Cestari, Renzo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Barrett esophagus; Dysplasia; FISH; Her 2 neu; Immunohistochemistry

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMATOXYLIN; PARAFFIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASSAY; BARRETT ESOPHAGUS; CHROMOSOME NUMBER; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE MARKER; DYSPLASIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

AGED; BARRETT ESOPHAGUS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 33748299461     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pdm.0000213455.22527.f7     Document Type: Article

References (44)

1. Bonino JA, Sharma P. Barrett's esophagus. Curr Opin Gastroenterol. 2005;21:461-465.
2. Shaheen NJ. Advances in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology. 2005;128:1554-1566.
3. Mueller J, Werner M, Stolte M. Barrett's esophagus: histopathologic definitions and diagnostic criteria. World J Surg. 2004;28:148-154.
4. Kyrgidis A, Kountouras J, Zavos C, et al. New molecular concepts of Barrett's esophagus: clinical implications and biomarkers. J Surg Res. 2005;125:189-212.
5. Bianco AR. Targeting c-erbB2 and other receptors of the c-erbB family: rationale and clinical applications. J Chemother. 2004;16(suppl 4):52-54.
6. Werner M, Mueller J, Walch A, et al. The molecular pathology of Barrett's esophagus. Histol Histopathol. 1999;14:553-559.
7. Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol. 1999;9:125-138.
8. Jankowski J, Coghill G, Hopwood D, et al. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut. 1992;33:1033-1038.
9. al-Kasspooles M, Moore JH, Orringer MB, et al. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993;54:213-219.
10. Flejou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol. 1994;47:23-26.
11. Ferrando I, Ferrando J, Reig G, et al. Barrett's esophagus, markers to distinguish risk groups. Rev Esp Enferm Dig. 1998;90:431-440.
12. Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35-39.
13. Walch A, Specht K, Bink K, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia- adenocarcinoma sequence of Barrett's esophagus. Lab Invest. 2001;81:791-801.
14. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
16. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
17. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech. 2002;59:102-108.
18. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer are we there yet? Am J Clin Pathol. 2004;121(suppl):S33-S49.
19. Hardwick RH, Shepherd NA, Moorghen M, et al. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol. 1995;48:129-132.
20. Press MF, Hung G, Godolphin W, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
21. Fornier M, Risio M, Van Poznak C, et al. HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park). 2002;16:1340-1348.
22. Persons DL, Bui MM, Lowery MC, et al. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci. 2000;30:41-48.
23. Hamilton SR, Aaltonen LA. WHO Pathology and Genetics: Tumors of Digestive System. Lyon: IARC Press; 2000.
24. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett's esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol. 2001;32:379-388.
25. Ishikawa T, Kobayashi M, Mai M, et al. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol. 1997;151:761-768.
26. Walch A, Bink K, Gais P, et al. Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol. 2000;20:25-32.
27. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol. 2000;53:890-892.
28. Ellis IO, Bartlett J, Dowsett M, et al. Best practice no 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004;57:233-237.
29. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol. 2001;19:2334-2356.
30. Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
31. Ronkainen J, Aro P, Storskrubb T, et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-1831.
32. Lagergren J. Adenocarcinoma of oesophagus: What exactly is the size of the problem and who is at risk? Gut. 2005;54(suppl I):i1-i5.
33. Playford RJ. The value of surveillance and other unresolved issues in the management of Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol. 2005;2:60-61.
34. Koppert LB, Wijnhoven BP, van Dekken H, et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol. 2005;92:169-190.
35. Schrump DS, Nguyen DM. Novel molecular targeted therapy for esophageal cancer. J Surg Oncol. 2005;92:257-261.
36. Fitzgerald RC, Triadafilopoulos G. Recent developments in the molecular characterization of Barrett's esophagus. Dig Dis. 1998;16:3-80.
37. Geddert H, Zeriouh M, Wolter M, et al. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and ist precursor lesions. Am J Clin Pathol. 2002;118:60-66.
38. Couturier J, Vincent-Salomon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol. 2000;13:1238-1243.
39. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
40. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
41. Birner P, Oberhuber G, Stani J, et al. Austrian Breast & Colorectal Cancer Study Group Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
42. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997;10:720-727.
43. Grushko TA, Blackwood MA, Schumm PL, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA-1 associated breast cancers. Cancer Res. 2002;62:1481-1488.
44. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.